Shopify’s Reset Sparks Stock Surge: What’s Next?by Mark Eisenberg 13.02.2024Shopify's Q4 earnings report is expected to showcase positive progress, with adjusted earnings per share of 30 cents, projected revenue ...
Bitcoin Surpasses $50K: What’s Next?by John Darbie 13.02.2024Bitcoin hits $50,000 milestone as investors celebrate positive factors, including surge in ETF inflows and upcoming halving. However, Solana network ...
Cadence Design Exceeds Expectations, Eyes Growthby Lilu Anderson 13.02.2024Cadence Design Systems reports strong Q4 results, surpassing analyst estimates for earnings per share and revenue. The company's stock has ...
SpaceX’s Starship Rocket Set for March Test Flightby Lilu Anderson 12.02.2024SpaceX's Elon Musk confirms that the Starship rocket is set for a test flight in March, a crucial milestone in ...
Crypto Whales Shift $350M as Bitcoin, Ethereum Soarby John Darbie 12.02.2024Wealthy crypto investors are moving $350 million in digital assets, mainly in Bitcoin and Ethereum. This suggests high activity and ...
GOP Concerns Over FDIC Fintech Policies: Transparency Neededby Mark Eisenberg 12.02.2024Three Republican members of the House Financial Services Committee have expressed concerns about the FDIC's policies on financial technology and ...
Dogecoin’s Price Potential: Breakout or Breakdown?by John Darbie 12.02.2024Dogecoin, the largest meme coin, could break out of its trading range with support at $0.075 and resistance at $0.088. ...
Intuitive Machines: Stock Surge Ahead of Lunar Questby Lilu Anderson 12.02.2024Intuitive Machines' stock soars as it prepares for a historic moon mission. A successful landing would be a major achievement ...
Pratt & Whitney’s Engine Tech Milestone: A Game-Changerby Mark Eisenberg 12.02.2024Raytheon Technologies' Pratt & Whitney achieves milestone in development of Next-Generation Adaptive Propulsion technology, moving closer to ground testing. Investors ...
Anixa’s Ovarian Cancer Trial Progress: Promising Resultsby Terry Bingman 12.02.2024Anixa Biosciences advances Phase 1 clinical trial for ovarian cancer therapy, increasing dosage and showing promising results. Market responds positively ...